The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).
 
John Davelaar
No Relationships to Disclose
 
Mourad Tighiouart
No Relationships to Disclose
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - FibroGen
 
Arsen Osipov
No Relationships to Disclose
 
Natalie Moshayedi
No Relationships to Disclose
 
Veronica Placencio-Hickok
Research Funding - Halozyme
Patents, Royalties, Other Intellectual Property - Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst)
 
Neil Bhowmick
No Relationships to Disclose
 
Jun Gong
Honoraria - Amgen; Astellas Pharma; Clinical Congress Consultants; Elsevier; Exelixis; QED Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; Clinical Congress Consultants; Elsevier; Exelixis; QED Therapeutics